Evaluation of the feasibility and efficacy of point-of-care antibody tests for biomarker guided management of COVID-19

By sjmartinez • September 14, 2024

Reilly C, Mylonakis E, Dewar R, Young B, Nordwall J, Bhagani S, Chia PY, Davis R, Files C, Ginde AA, Hatlen T, Helleberg M, Hayanga A, Jensen TO, Jain MK, Kalomenidis I, Kim K, Lallemand P, Lindegaard B, Menon A, Ognenovska K, Poulakou G, Thorup Røge B, Rogers AJ, Shaw-Saliba K, Sandkovsky U, Trautner BW, Vasudeva SS, Vekstein A, Viens K, Wyncoll J, DuChateau B, Zhang Z, Wu S, Babiker AG, Davey V, Gelijns A, Higgs E, Kan V, Lundgren J, Matthews GV, Lane HC. Evaluation of the feasibility and efficacy of point-of-care antibody tests for biomarker guided management of COVID-19. J Infect Dis. 2024 Sep 12:jiae452. doi: 10.1093/infdis/jiae452. Epub ahead of print. PMID: 39269490.

Tags: antibody tests, biomarkers, covid-19, Harbor UCLA, Infectious Diseases, point-of-care tests, Publications

Regular Insulin Versus NPH Insulin for Continuous Enteral Tube Feeding in Hospitalized Patients

Kalangi ST, Bokka SM, Anand S, Garg R. Regular Insulin Versus NPH Insulin for Continuous Enteral Tube Feeding in Hospitalized Patients. Clin Diabetes. 2025 Apr[...]

Antiretroviral Therapy Intensification With Dolutegravir and/or Maraviroc Did Not Affect HIV-1 Cell-Associated DNA, RNA, and 2–LTR Circles Over 12 Weeks

Reed JC, Hall L, McKhann A, Kwak G, Goecker EA, Coombs RW, Chen H, Roa J, Vecchio A, Daar ES, Hunt PW, Marra CM, Campbell[...]

Lipoprotein(a), family history, and incidence of premature ASCVD events in a pooled US cohort

Fan Y, Fan W, Hu X, Tsai MY, Hoogeveen RC, Budoff MJ, Wong ND. Lipoprotein(a), family history, and incidence of premature ASCVD events in a[...]